Underestimating the potential of CHM, when compared to the...

Underestimating the potential of CHM, when compared to the market cap now, is in itself a kind of underestimate : )

4 clinical trials, all Novel and cutting edge, with three of them showing data that exceeds what is currently available from SOC drugs. We haven't heard about the Cd17 drug yet, but Bec seems excited about that one too!

If the financial pathway was fixed, this would be 10 to 25 bags from where it is now. And thats even in this market.

The financial pathway is the risk. Until this is sorted, this is a very high-risk investment. But at this market cap, even including future dilution, large gains could be made, If!!!! the financials are sorted.